alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
IN THE SUPREME COURT, STATE OF WYOMING

2023 WY 7

 October Term, A.D. 2022

January 25, 2023

BOARD OF PROFESSIONAL 

RESPONSIBILITY, WYOMING 

STATE BAR,

Petitioner,

v.

SAMUEL P. KRONE, WSB # 6-3534,

Respondent.

D-16-0005

ORDER REINSTATING ATTORNEY TO THE PRACTICE OF LAW

[¶1] This matter came before the Court upon a Report and Recommendation for 

Reinstatement, filed herein January 17, 2023, by a review panel of the Board of 

Professional Responsibility for the Wyoming State Bar, pursuant to a stipulation. By order 

entered May 31, 2018, this Court disbarred Respondent, with the period of disbarment 

beginning August 24, 2016. Bd. of Pro. Resp., Wyoming State Bar v. Krone, 2018 WY 55, 

418 P.3d 253 (Wyo. 2018). Respondent subsequently sought reinstatement. See Rule 22, 

Wyoming Rules of Disciplinary Procedure. Now, after a careful review of Report and 

Recommendation for Reinstatement and the file, this Court finds the Report and 

Recommendation should be approved, confirmed and adopted by the Court and that 

Respondent Samuel P. Krone should be reinstated to the practice of law. It is, therefore, 

[¶2] ADJUDGED AND ORDERED that the Board of Professional Responsibility’s 

Report and Recommendation for Reinstatement, filed herein January 17, 2023, which is 

attached hereto and incorporated herein, shall be, and the same hereby is, approved, 

confirmed and adopted by this Court; and it is further

[¶3] ADJUDGED AND ORDERED that the Respondent, Samuel P. Krone, be, and 

hereby is, reinstated to the practice of law in Wyoming, effective immediately; and it is 

further 
[¶4] ORDERED that, pursuant to Rule 9(b) Wyoming Rules of Disciplinary Procedure, 

this Order Reinstating Attorney to the Practice of Law, along with the incorporated Report 

and Recommendation for Reinstatement, shall be published in the Wyoming Reporter and 

the Pacific Reporter; and it is further

[¶5] ORDERED that the Clerk of this Court shall docket this Order Reinstating Attorney 

to the Practice of Law, along with the incorporated Report and Recommendation for 

Reinstatement, as a matter coming regularly before this Court as a public record; and it is 

further

[¶6] ORDERED that the Clerk of this Court transmit a copy of this Order Reinstating 

Attorney to the Practice of Law to the members of the Board of Professional Responsibility 

and to the clerks of the appropriate courts of the State of Wyoming.

[¶7] DATED this 25th day of January, 2023.

BY THE COURT:

/s/

KATE M. FOX

Chief Justice
**EXHIBIT
      32.2**





**CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO SECTION 906**


**OF
      THE SARBANES-OXLEY ACT OF 2002**





Pursuant
      to 18 U.S.C. Section 1350, the undersigned Officer of Opexa Therapeutics, Inc.
      (the “Company”), hereby certifies, to such officer’s knowledge, that the
      Company’s Annual Report on Form 10-KSB for the year ended December 31, 2006 (the
“Report”) fully complies with the requirements of Section 13(a) or Section
      15(d), as applicable, of the Securities Exchange Act of 1934 and that the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.











/s/
      LYNNE HOHLFELD


Lynne
      Hohlfeld


Chief
      Financial Officer and Principal Accounting Officer








Date:
      November 9, 2007
Ex 10.6



Exhibit 10.6  Agreement with Muna, Inc.



MUNA INC
P.O. Box 970045, Coconut Creek, F1 33097    954-344-1493    munain@bellsouth.net

David W. Moskowitz, MD, MA, FACP
GenoMed, LLC
4560 Clayton Avenue
St. Louis, MO 63110

Re: Proposal for Hispanic population sample collections

Dear Dr. Moskowitz:


Pursuant to our discussions concerning the collection of samples from Hispanic
populations, Muna Inc has a network of physicians and clinics with a high
percentage of Hispanic patients. We have reviewed the possible disease states
that you have expressed interest in investigating. We can provide access to most
of the samples you seek as expressed in our recent email. Muna Inc is prepared
to begin collections of samples upon written confirmation of the following
proposal.

Muna Inc will arrange for the collection of blood from Hispanic patients with
documented disease states as per GenoMed specifications. Blood will be collected
in 5-ml purple top tubes and stored refrigerated pending shipment to GenoMed.
Samples will be shipped refrigerated to GenoMed using GenoMed's designated
shipper and account number.

Cost per sample win be $20/tube. Payments to be made for each shipment by check
made payable to Muna Inc within 2 weeks of receipt of samples. Documentation
requirements for the samples has yet to be finalized. Normal documentation of
samples (simple demographics and stated disease state) is included in the above
costs.

If documentation is to be provided in computer database format to be specified
by GenoMed, this service can be provided at little or no additional cost per
sample (depending on the complexity of the database requirements). Some initial
setup costs are anticipated. An initial fee of $3-5000 (again depending on the
complexity of the database) will be required for the proper training of network
staff for data entry purposes. If onsite dedicated computer hardware is
required, that cost will be additional, however, we do anticipate that existing
equipment will accommodate most database entry requirements.

A timetable for the collection of samples can best be provided after the
collection process has begun. While our clinics can assure their existing
patient loads, not all patients available to these clinics will be willing to
participate in his program. Of course, physicians will be instructed to
concentrate on disease states as specified by GenoMed.

By the designated signatures below, Muna Inc and GenoMed LLC agree in principle
to the above proposal. Upon authorization, Muna Inc will initiate the collection
process. Collections will continue until the program is completed or until
either party notifies the other that collections are be terminated. GenoMed will
be responsible for payment upon delivery of all samples collected prior to
notice to terminate.


/s/ David W. Moskowitz      1/16/02       /s/ Leo A. Gosser           12/7/01
David W. Moskowitz, MD      Date              Leo A. Gosser, Ph.D     Date
GenoMed LLC                                   MUNA Inc.
I 

111TH CONGRESS 

2D SESSION H. R. 5030 

To amend the Internal Revenue Code of 1986 to allow distributions from 

529 plans for the payment of student loans. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 15, 2010 

Ms. BEAN (for herself, Mr. KIND, Mrs. HALVORSON, Ms. MARKEY of Colorado, and Mr. NYE) introduced the following bill; which was referred to 

the Committee on Ways and Means 

A BILL 

To amend the Internal Revenue Code of 1986 to allow distributions from 529 plans for the payment of student 

loans. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘College Savings Flexi5 bility Act of 2010’’. 

mstockstill on DSKH9S0YB1PROD with BILLS

2 

•HR 5030 IH

1 SEC. 2. 529 PLAN DISTRIBUTION FOR STUDENT LOAN PAY2 MENTS. 

3 (a) IN GENERAL.—Paragraph (3) of section 529(e) 

4 of the Internal Revenue Code of 1986 is amended by add5 ing at the end the following new subparagraph: 

6 ‘‘(C) TEMPORARY RULE FOR STUDENT

7 LOANS.—For purposes of this paragraph, any 

8 interest or principal paid after December 31, 

9 2009, and before January 1, 2015, with respect 

10 to a qualified education loan (as defined in sec11 tion 221) with respect to a designated bene12 ficiary shall be treated as a qualified higher 

13 education expense.’’. 

14 (b) CONFORMING AMENDMENTS.— 

15 (1) Subparagraph (A) of section 72(t)(7) of 

16 such Code is amended by inserting ‘‘determined 

17 without regard to subparagraph (C) thereof’’ after 

18 ‘‘section 529(e)(3)’’. 

19 (2) Clause (i) of section 530(b)(2)(A) of such 

20 Code is amended by inserting ‘‘determined without 

21 regard to subparagraph (C) thereof’’ after ‘‘section 

22 529(e)(3)’’. 

23 (c) EFFECTIVE DATE.—The amendments made by 

24 this section shall apply to distributions made after Decem25 ber 31, 2009. 

Æ 

mstockstill on DSKH9S0YB1PROD with BILLS
Exhibit 32.1  CERTIFICATION  PURSUANT TO THE SARBANES-OXLEY ACT 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002   I, John Swallow, CEO, and Chairman of the Board of Directors of Timberline Resources Corporation (the Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:  1.  This amended Quarterly Report on 10QSB of the Company for the period ended June 30, 2006 as filed with the Securities and Exchange Commission (the report), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  2.  The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.  Date: February 7, 2007.  /s/ John Swallow  _______________________ John Swallow (CEO and Chairman of the Board of Directors)
<PAGE>


                             [MAXXIM MEDICAL LOGO]

           TERMS OF RETENTION AGREEMENT/ADDENDUM TO SUMMARY TERMS OF
                            EMPLOYMENT AS OF 9-20-2000

                                November 1, 2001

I.   Employer/Company: Maxxim Medical, Inc.

II.  Employee: Paulee C. Day

III. Title: Corporate Vice President, General Counsel and Secretary

IV.  Guaranteed Term of Employment: November 1, 2001 - October 31, 2002

V.   Guaranteed Annual Base Salary: no less than $130,000, to be paid in
     bi-weekly installments

VI.  Retention Bonus: Employee shall receive the following:

     A.   Continuation of benefits in effect as of Employee's last day of
          employment at Company's expense for twelve (12) months, which shall
          commence on the day immediately following Employee's last day of
          employment with the Company,
     B.   Twelve (12) months' salary, based on Annual Base Salary above or the
          annual salary then in effect, whichever is higher, due and payable as
          follows:
          1.   The first six (6) months of the Retention Bonus shall be paid to
          Employee immediately upon execution hereof. Such amount shall vest
          ratably with each day that Employee is employed by Company beginning
          on November 1, 2001 and ending six (6) months later, on April 30,
          2002, at which time the entire amount shall be fully vested. In the
          event that Employee voluntarily terminates her employment with Company
          prior to April 30, 2002, Employee shall repay to Company the unvested
          portion of such payment. Provided, however, that if Employee's reasons
          for terminating her employment are those described in Section
          VI(B)(2)(iii) or Section VI(B)(2)(iv) immediately below, all amounts
          shall immediately vest and no payment shall be due to the Company by
          Employee.
          2.   The final six (6) months of the Retention Bonus, such amount to
          be no less than $65,000, shall be paid immediately upon the earlier
          of:
               (i)   November 1, 2002;
               (ii)  at such time that Employer terminates employment of
                     Employee on or before October 31, 2002 without "Good
                     Cause" as defined in Section VII below;
               (iii) upon Employee's termination of employment following a
                     substantial change in the job duties, office location or
                     condition of employment as in effect as of the date
                     hereof; or
               (iv)  upon Employee's termination of employment following a
                     breach of the terms of this Agreement by Employer or a
                     change in any of the terms hereof without Employee's
                     prior written consent.
#### IN THE MATTER OF THE ADOPTION OF ROBERT CECIL COOKE, III, GLENDA FAYE PEELE, Petitioner v. ROBERT C. COOKE, JR.

No. 7412SC1012

(Filed 7 May 1975)

Adoption § 2— abandonment of child — incompetent evidence

In a trial to determine whether respondent had abandoned his child and was thus not a necessary party to an adoption proceeding instituted by the child’s stepfather, the trial court erred in the admission of evidence of proper custody, the suitability of the stepfather as an adoptive parent and whether adoption of the child by the stepfather might be in the best interests of the child.

Appeal by respondent from *Hobgood, Judge.*Judgment entered 30 August 1974 in Superior Court, Cumberland County. Heard in the Court of Appeals 14 February 1975.

Respondent, Robert Cooke, is the father of Robert Cooke III, who was born of the marriage of respondent and Glenda Cooke (now married to Sidney Peele and known as Glenda Peele.).

Sidney Peele filed a petition to adopt the child. The court was asked to declare that respondent had abandoned the child and was, therefore, not a necessary party to the adoption proceeding. Respondent denied the abandonment and the issue was transferred to the Superior Court for trial.

The jury determined that respondent had willfully abandoned the child for at least six consecutive months immediately preceding institution of the proceeding.

*674
      *■ Bobby G. beaver, for petitioner appellee.*

*. Henry L. Anderson, Jr., for defendant appellant.*

VAUGHN, Judge.

Since there must be a new trial we will refrain from a recital of the evidence and say only that the conflicting inferences and conclusions arising therefrom presented a close question for the jury. The errors at trial are, therefore, especially prejudicial to respondent.

. . The sole issue at trial was whether respondent had abandoned his child.

The questions of proper custody, the suitability of Sidney Peele as an adoptive parent and whether adoption of the child by Peele might be in the best interests of the child were not for consideration by the jury. Nevertheless, incompetent and irrelevant evidence on these matters was allowed, over respondent’s objection, to such an extent that it undoubtedly influenced if, indeed, it did not dominate, the jury’s deliberations.

New trial.

Judges Parker and Martin concur.
**Exhibit
      32(a)**





**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**





In
      connection with the Quarterly Report on Form 10-Q of New River Pharmaceuticals
      Inc. (the “Company”) for the period ending April 2, 2006, as filed with the
      Securities and Exchange Commission on the date hereof (the “Report”), I, Randal
      J. Kirk, Chairman, President and Chief Executive Officer of the Company,
      certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
      Sarbanes-Oxley Act of 2002, that:





(1) the
      Report fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2) the
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.







/s/
                Randal J. KirkRandal
                J. KirkChairman,
                President andChief
                Executive Officer(Principal
                executive officer)May
                12, 2006
<PAGE>



                                                                  Exhibit 99.54

                              JOINT ACKNOWLEDGEMENT
                              ---------------------




This Acknowledgement is delivered in connection with the consulting agreement 
(the "Consulting Agreement") dated as of May 13, 1997 between First Dynasty 
Mines Armenia Limited (formerly Global Gold Armenia Limited) ("FD Armenia") 
and Robert A. Garrison ("Garrison").

FD Armenia and Garrison have agreed pursuant to section 3 of the Letter 
Agreement dated for reference the 24th day of July, 1998 between First 
Dynasty Mines, Global Gold Corporation, and Garrison to terminate the 
Consulting Agreement.

The undersigned hereby acknowledge that the Consulting Agreement is hereby 
terminated and, as such, all the rights, duties and obligations of each of FD 
Armenia and Garrison to each other arising out of or related to the 
Consulting Agreement are hereby terminated.

The undersigned also hereby acknowledge that each of FD Armenia and Garrison 
are hereby released and discharged absolutely and forever from any further 
obligations in respect of the Consulting Agreement.

Dated this  31st  day of  August, 1998.
          -------       --------

FIRST DYNASTY MINES ARMENIA LIMITED



Per:/s/ MP Randolph                             /s/ Robert Garrison
    --------------------------------            -------------------------------
         Authorized Signatory                   ROBERT A. GARRISON
Exhibit 32.2
                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual report on Form 10K of ATEL Cash  Distribution Fund
VIII,  LP, (the  "Company") for the period ended December 31, 2003 as filed with
the Securities and Exchange  Commission on the date hereof (the  "Report"),  and
pursuant  to  18  U.S.C.   ss.1350,   as  adopted  pursuant  to  ss.906  of  the
Sarbanes-Oxley  Act of 2002, I, Paritosh K. Choksi,  Chief Financial  Officer of
ATEL Financial  Services,  LLC,  managing member of the Company,  hereby certify
that:

1. The Report fully complies with the  requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934 ; and

2. The  information  contained in the Report  fairly  presents,  in all material
respects, the financial condition and results of operations of the Company.

Date:        3/26/2004



/s/ Paritosh K. Choksi
---------------------------
Paritosh K. Choksi
Executive Vice President of General
Partner, Principal financial officer of registrant
**Avis juridique important**

*|*

# 32000D0345

**2000/345/EC: Commission Decision of 22 May 2000 setting the date on which dispatch from Portugal to Germany of certain products for the purpose of incineration may commence by virtue of Article 3(6) of Decision 98/653/EC (notified under document number C(2000) 1367) (Text with EEA relevance)***Official Journal L 121 , 23/05/2000 P. 0009 - 0009*

Commission Decision

of 22 May 2000

setting the date on which dispatch from Portugal to Germany of certain products for the purpose of incineration may commence by virtue of Article 3(6) of Decision 98/653/EC

(notified under document number C(2000) 1367)

(Text with EEA relevance)

(2000/345/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Directive 89/662/EEC of 11 December 1989 concerning veterinary checks in intra-Community trade with a view to the completion of the internal market(1), as last amended by Directive 92/118/EEC(2),

Having regard to Commission Decision 98/653/EC of 18 November 1998 concerning emergency measures made necessary by the occurrence of bovine spongiform encephalopathy in Portugal(3), as last amended by Decision 2000/104/EC(4), and in particular Article 3(6) thereof,

Whereas:

(1) Article 3(6) of Decision 98/653/EC requires the Commission to set the date on which dispatch of products referred to in this Article may commence, after having carried out Community inspections and after having informed the Member States.

(2) An inspection carried out by the Commission services in Germany from 27 to 29 February 2000, in particular to assess the veterinary checks pursuant to Article 3 of and Annex I to Decision 98/653/EC have shown that the conditions are complied with satisfactorily,

HAS ADOPTED THIS DECISION:

Article 1

The date referred to in Article 3(6) of Decision 98/653/EC shall be 22 May 2000 for dispatch to Germany of products referred to in this Article.

Article 2

This Decision is addressed to the Member States.

Done at Brussels, 22 May 2000.

For the Commission

David Byrne

Member of the Commission

(1) OJ L 395, 30.12.1989, p. 13.

(2) OJ L 62, 15.3.1993, p. 49.

(3) OJ L 311, 20.11.1998, p. 23.

(4) OJ L 29, 4.2.2000, p. 36.
# Transfer of Funds from FY 2004 and 2005 Foreign Assistance Act and Arms Export Control Act Accounts to the International Narcotics Control and Law Enforcement Account to Support the G-8 Women's Justice and Empowerment Initiative 

# Memorandum for the Secretary of State

Pursuant to the authority vested in me by the Constitution and laws of the United States, including section 610 of the Foreign Assistance Act of 1961, as amended (the “Act”), I hereby determine it necessary for the purposes of that Act that $5 million in FY 2004 funds made available under the Support for East European Democracy Act ($1 million) and FY 2005 funds made available under chapter 9 of part II of the Act ($1.2 million) and under section 23 of the Arms Export Control Act ($2.8 million) be transferred to, and consolidated with, funds made available under chapter 8 of part I of the Act, and such funds are hereby so transferred and consolidated. 

                    You are hereby authorized and directed to report this determination to the Congress and to publish it in the                     **Federal Register**                    .                

[FR Doc. 05-20856

Billing code 4710-10-P